...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer letters >Molecular imaging in pancreatic cancer - A roadmap for therapeutic decisions
【24h】

Molecular imaging in pancreatic cancer - A roadmap for therapeutic decisions

机译：胰腺癌中的分子成像 - 治疗决策的路线图

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in United States with an overall 5-year survival of 5% [1]. Despite remarkable advances in the past two decades that have greatly improved our understanding of the pathobiology of PDAC, overall median survival in PDAC is a dismal 8-12 months in patients with localized disease, and 4-6 months in patients with metastatic disease [2]. These alarming statistics are due to multiple factors, including the paucity of specific symptoms even when PDAC is already well-established, the absence of specific and sensitive markers that would allow for early stage diagnosis, and the advanced stage at presentation which precludes resection. Moreover, there is a high recurrence rate following resection, and most therapeutic approaches are of limited effectiveness due to intrinsic chemoresistance and radiore-sistance of the cancer cells, and the presence of a dense stroma rich in collagens and mucins that combine to prevent therapeutic agents from penetrating the tumor mass. Together, these alterations exacerbate response to therapy [3,4], and even new combinatorial treatment regimens only prolong survival for a few months [5].
机译：胰腺导管腺癌（PDAC）是美国癌症相关死亡的第四个主要原因，总体5年生存率为5％[1]。尽管过去二十年来，但对PDAC病理到病理生物学的理解有了很大的进展，但PDAC的总体中位生存率是局部疾病患者的8-12个月，转移疾病患者4-6个月[2 ]。这些惊人的统计数据是由于多种因素，包括缺乏特异性症状的缺乏，即使PDAC已经确定，没有特异性和敏感的标志物，可以允许早期诊断，并在介绍切除的介绍中的晚期阶段。此外，切除后存在高复发率，大多数治疗方法由于癌细胞的内在化学抑制和含射腺瘤而导致的有效性有限，以及富含胶原蛋白和粘蛋白的致密基质的存在以防止治疗剂从渗透肿瘤质量。在一起，这些改变加剧了对治疗的反应[3,4]，甚至甚至新的组合治疗方案甚至只延长了几个月的存活[5]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号